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specificity of next-generation sequencing for
detection of simple and complex mutations
Ephrem LH Chin, Cristina da Silva and Madhuri Hegde*Background: Detecting mutations in disease genes by full gene sequence analysis is common in clinical diagnostic
laboratories. Sanger dideoxy terminator sequencing allows for rapid development and implementation of
sequencing assays in the clinical laboratory, but it has limited throughput, and due to cost constraints, only allows
analysis of one or at most a few genes in a patient. Next-generation sequencing (NGS), on the other hand, has
evolved rapidly, although to date it has mainly been used for large-scale genome sequencing projects and is
beginning to be used in the clinical diagnostic testing. One advantage of NGS is that many genes can be analyzed
easily at the same time, allowing for mutation detection when there are many possible causative genes for a
specific phenotype. In addition, regions of a gene typically not tested for mutations, like deep intronic and
promoter mutations, can also be detected.
Results: Here we use 20 previously characterized Sanger-sequenced positive controls in disease-causing genes to
demonstrate the utility of NGS in a clinical setting using standard PCR based amplification to assess the analytical
sensitivity and specificity of the technology for detecting all previously characterized changes (mutations and
benign SNPs). The positive controls chosen for validation range from simple substitution mutations to complex
deletion and insertion mutations occurring in autosomal dominant and recessive disorders. The NGS data was 100%
concordant with the Sanger sequencing data identifying all 119 previously identified changes in the 20 samples.
Conclusions: We have demonstrated that NGS technology is ready to be deployed in clinical laboratories.
However, NGS and associated technologies are evolving, and clinical laboratories will need to invest significantly in
staff and infrastructure to build the necessary foundation for success.
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The introduction of next-generation sequencing (NGS) has
revolutionized the way sequencing is being conducted in
many research and clinical laboratories. Large genome
centers have been the early adopters of NGS and use it
primarily for large-scale genome sequencing projects [1-3].
A single next-generation instrument is able to sequence a
whole human genome at 7.4-fold coverage in two months
[2]. In comparison, the International Human Genome
Sequencing Consortium of 20 laboratories worldwide took
approximately 15 months to perform the same work [4].
There are currently four major manufacturers of next-
generation instruments, and they all share the same* Correspondence: mhegde@emory.edu
Department of Human Genetics, Emory University, Michael Street, Atlanta,
GA, USA
© 2013 Chin et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfundamental process using four different chemistries [5].
Third-generation sequencers, like the Ion Torrent and
Pacific Biosciences systems, have emerged as viable
alternatives to the four next-generation sequencers and
have started to appear in laboratories [6,7].
In the last few years, clinical laboratories have begun to
investigate how best to use the prodigious data-generation
capacity of the NGS for clinical testing, as this tremendous
sequencing capacity opens up new diagnosis possibilities
that Sanger sequencing technology could not offer.
Automated dideoxy Sanger sequencing has been the work-
horse in clinical laboratories for many years and is
considered to be the “gold standard” [8]. Clinical sequen-
cing assays using Sanger sequencing are easy to develop
and can be deployed rapidly in a clinical laboratory; how-
ever, it has limited data-generation capacity, mainly due tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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most a few genes in a patient. Accurate and sensitive
mutation identification are of paramount importance
for diagnosis confirmation, genetic counseling, risk
assessment, and carrier screening in patients and
family affected with a genetic disorder. The ability of
a single next-generation sequencer to generate massive
amounts of data allows a laboratory the opportunity to
analyze many more genes in a cost-effective manner [9].
Many possible candidate genes for a specific phenotype
can be investigated with ease, and NGS will allow regions
of a gene not typically tested for mutations, such as deep
intronic and promoter regions, to be analyzed on a rou-
tine basis. Here, we tested the analytical sensitivity and
specificity of NGS for application in a clinical setting using
previously identified simple and complex mutations.
The goal during a standard laboratory test development
and validation process is to ensure the accuracy of the
reported results. To achieve accuracy of results, laboratories
have to ensure that every step of the testing process is care-
fully evaluated, and results documented to prove that a
procedure works as expected and can consistently achieve
the expected result. For a laboratory-developed test (LTD),
laboratories are charged with establishing the following for
the test: accuracy, precision, analytical sensitivity, analytical
specificity, the reported range of test results, the test’s nor-
mal values, and the efficiency of the call rate for genotyping
assays as indicated by the Center for Disease Control and
Prevention, ACCE Model Process for Evaluating Genetic
Tests as of January 3, 2010 (http://www.cdc.gov/genomics/
gtesting/ACCE/). The analytical sensitivity of an assay is its
ability to detect a low concentration of a given substance in
a biological sample [10]. The sensitivity of NGS is vastly
superior to Sanger sequencing and is capable of detecting
mutant alleles as low >5%, as in mitochondria testing [11].
This extreme low level of the mutant allele will be
undetectable by conventional Sanger sequencing and may
not be confirmed as a “real” change. In our study, we are
looking at two possibilities: equal proportion of both
mutant and wild-type alleles, and either a mutant
allele or a wild-type allele. The analytical specificity of
an assay is its ability to identify only a specific
substance [10]. In this study, we have assessed NGS
for its application in clinical testing.
Methods
Validation samples selected for this study
For the first validation SOLiD sequencing run, we selected
20 samples that were referred to our laboratory for Sanger
sequencing for a variety of different single-gene disorders.
The selection of validation samples was based on the type
of mutation present in the sample, the number of exons in
the gene, and the complexity of the gene, which included %
GC, sequence context around the mutation. The followinggenes were included: ACADVL, BCKDHA, CBS, CFTR,
DMD, GAA, GALC, GALT, GBA, GJB2, HEXB, IDUA,
OPA1, RECQL4, SGSH, SMPD1, and ZEB2. Samples
selected for use in the validation of the SOLiD v3 instru-
ment carried 119 changes consisting of 102 missense
changes, seven deletions, nine duplications/insertions,
and one indel mutation. These changes were initially
identified by standard conventional Sanger clinical se-
quencing assays.
DNA isolation and sample enrichment
Genomic DNA was purified from peripheral blood or saliva
samples (DNA Genotek) using standard extraction con-
ditions as recommended by the Puregene DNA extraction
system (Qiagen). The coding region and at least 20 bp of
the flanking intronic sequence were amplified using
custom-designed primers (Additional file 1) using the
FastStart Taq PCR system (Roche Applied Sciences). PCR
products ranged in size from 250 bp to 750 bp. PCR
amplifications were performed in 50-ul reactions using
50 ng of genomic DNA, 10X reaction buffer, 0.2 mM of
each dNTP, 2 pM of each forward and reverse primer, and
2U of Taq polymerase. The cycling condition consisted of
an initial denaturation at 95C for 3 min, 10 cycles of step-
down annealing, where there was a decrease of 0.5C at
each cycle following the initial condition of 1 min denatu-
ration at 95C, 1 min of annealing at 60C, and extension
for 1 min at 72C. 25 cycles of minute denaturation
at 95C, 1 min of annealing at 55C, and extension
for 1 min at 72C and a final 7-min extension at
72C. After amplification the PCR products were
visualized on a 2% agarose gel and purified with
Millipore MultiScreen PCR UF 96-well plates (Millipore).
Enriched amplicons were quantitated in triplicate
using PicoGreen (Life Technologies) and pooled in
equimolar amounts.
Next-generation sequencing (NGS) analysis on an ABI
SOLiD v3 sequencer
Each pooled sample was end-repaired (Epicenter Bio-
technologies) and concatenated (New England BioLabs)
using the manufacturer’s standard instructions. Results of
concatenation were checked using an Agilent Bioanalyzer
DNA 7500 chip (Agilent) to ensure that individual PCR
fragments had been joined end to end to form a larger
molecular weight product. Concatenated sample was then
sheared randomly using Covaris S2 sonicator, and the
sample was checked using an Agilent Bioanalyzer DNA
7500 chip to ensure that sheared sample was within
150 bp to 180 bp. Shearing concatenated sample ensures
that we have even, non-biased coverage across the regions
of interest . Sheared samples were then end-repaired and
sequencing adaptor with unique barcode attached to each
sample. An Agilent Bioanalyzer high-sensitivity chip was
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size should be increased by 90 bp after ligation, to a size
range of 240 bp to 270 bp. Each sample was then ampli-
fied using Platinum Taq PCR system and SOLiD fragment
library oligo kit (Life Technologies). Samples were then
quantified using an Agilent Bioanalyzer high-sensitivity
chip. Quantification of each sample was performed by
calculating the area under the peak using the Agilent
Bioanalyzer manual integration feature. Each sample is
diluted to 1 ng/ul and all 20 individually barcoded samples
are pooled together to create a single SOLiD library.
Barcoding allows multiple small enriched targets to be
combined and analyzed. The SOLiD library containing all
20 barcoded samples were diluted to 60 pg/ul, and emul-
sion PCR using the Solid ePCR kit (Life Technologies)
was performed at two titration points (1pM and 1.5pM).
Beads were purified and enriched for beads that had amp-
lified template attached. Beads were then quantified using
a NanoDrop and an estimated 15 million beads were used
to perform a work flow analysis (WFA) on a quad on the
SOLiD instrument. Approximately 15 million beads
were deposited on a single quad on the glass slide (Life
Technologies). Data generated on the WFA run were then
used to determine the quality and quantity of beads
present in the sample. Using quantification data from the
WFA run, 60 million beads were then deposited onto a
new quad, and a 50-bp barcoded fragment sequencing run
was performed on the SOLiD v3 instrument.Data analysis
Data were analyzed using a software package that was
commercially available: NextGENe™ (SoftGenetics LLC).
Raw data from the 20 samples were analyzed in
NextGENe™ according to the manufacturers’ standard
analysis process. A single nucleotide polymorphism
(SNP) detection and small and large indel-calling algo-
rithm was run. Two projects were created per sample;
one with the 50-bp reads from each individual sample
was aligned back against reference sequence, which was
downloaded from NCBI. The second was running up to
four cycles of condensation for each sample to ensure
that small and large indels were detected. Analysis on
NextGENe™ was performed on a dual quad core run-
ning at 3.33 GHz desktop computer with 48 GB of RAM
and 1 TB of storage.Mutation and polymorphism nomenclature
The reference sequence used for the 20 samples is as
follows in Table 1. Nucleotide numbering reflects the
cDNA numbering, with +1 corresponding to the A nu-
cleotide of the ATG translation initiation codon in the
reference sequence. The initiation codon is codon 1.Results
Pooled PCR
Despite considerable work to ensure that each coding
region of the entire library is represented equally during
pooling, there is still great variability in the laboratory
process that was hard to control. There seems to be
lower coverage in the first coding exon of each of the 20
samples in this run, which may be due to the presence
of higher GC content, whereas some additional exons
gave a low coverage or no coverage (Table 2).
Target matched reads
In this run, a single quad generated 38,779,652 50-bp
reads on the ABI SOLiD v3 instrument, which equated
to 1,939 gigabases of data. Data generated from this run
provided in excess of 1.9 million 50-bp reads per sample
(Table 3). Approximately 53% of the 1.9 million 50-bp
reads were good-quality data and mapped to the genes
of interest, providing approximately an average of 71,000
reads per coding region and in excess of 9,800 reads per
base. This indicates that our analytical specificity of
good-quality reads is at 100% [12]. While we were able
to identify all 119 expected changes as identified with
our Sanger sequencing assay results, this data set had
nine false-positive changes, which brought the analytical
sensitivity of this study in at 92.7% [12].
Data analysis
Initial analysis with the NextGENe™ software was able to
detect 119 out of the 119 expected changes (Table 4). Three
changes (IDUA c.973-45 G >C, OPA1 c.93_96dupAAAA
and SGSH c.664-39_664-38delCT) missed during the initial
analysis were complex changes or changes at the end of
PCR fragments, where good-quality data were found to be
discarded due to the initial software setting. The entire data
set were subjected to analysis to determine the quality of
each 50-bp read, with good-quality reads retained for add-
itional analysis and bad-quality reads removed from ana-
lysis. The additional rounds of analysis performed on
NextGENe™ used only good-quality reads for alignment
for the three samples for which mutations were missed.
This alternative strategy enabled the laboratory to detect
the remaining three mutations that were missed in initial
phases of the data analysis, and we were successful in
detecting all 119 changes present in the data set.
NextGENe™ was not only able to detect single nucleotide
changes, such as ACADVL c.1504C >G (p.L502V), but also
small deletions and insertion events, such as CFTR
c.1521_1523delCTT and CFTR c.2052_2053insA. The real
power of NextGENe software was its ability to detect larger
deletions, duplications, and indels, such as SMPD1
c.785_807del23, SGSH c.337_345delins11, and GBA
c.1265_1317del55, using data generated from a 50-bp frag-
ment sequencing run by applying a SoftGenetic’s propriety
Table 1 Validation sample changes
Gene Reference Change Coverage Phred-like confidence Score % WT % Mut A% C% G% T% Ins% Del%
ACADVL NM_000018.2 c.-63_-49dupGGGCGTGCAGGACGC
c.1375_1376insC 10663 31.5 NA 32 31.93
c.1504C > G (p.L502V) 9193 31 60 38 1.5 58.57 37.59 2.3 0.00 0.04
c.1605 + 6 T > C 5733 19.7 68 28 1.71 28.14 2.62 67.54 0.00 0.00
BCKDHA_1 NM_000709.3 c.118dupC 21692 29.5 NA 19 19.21
c.370C > T (p.R124W) 18217 32.3 58 39 1.77 58.36 0.48 39.35 0.00 0.04
BCKDHA_2 NM_000709.3 c.972C > T (p.F324) 15574 30.7 6 91 1.44 5.91 1.36 91.29 0.00 0.01
c.995 + 26C > T 18624 33.7 57 41 0.61 57.17 0.85 41.36 0.03 0.02
c.995 + 49 G > A 23230 30.3 6 92 91.90 1.10 6.00 0.96 0.00 0.04
c.996-33dupC 15037 30.8 NA 75 74.61
CBS NM_000071.2 c.959 T > C (p.V320A) 8715 24.4 7 91 0.48 90.82 1.63 7.05 0.00 0.02
c.1080C > T (p.A360) 5125 27.3 53 46 0.76 52.55 0.62 46.07 0.00 0.00
CFTR NM_000492.3 c.1408 G > A (p.M470V) 9356 30.4 60 38 38.44 0.46 60.04 0.99 0.00 0.07
c.1521_1523delCTT 5843 22.3 NA 19 0.21 80.35 0.22 0.21 0 19.01
c.2052_2053insA 7714 24 NA 26 25.68
DMD NM_004006.2 c.2645A > G (p.D882G) 2974 19.6 5 93 4.98 0.87 92.67 1.48 0 0
c.5234 G > A (p.R1745H) 4289 23.4 4 93 93.38 1.19 4.13 1.31 0 0
c.5326-22 G > T 162 9.6 3 91 3.7 1.85 3.09 91.36 0 0
c.6290 + 27 T > A 4085 22.9 3 94 94.15 1.35 1.98 2.5 0 0.02
c.8810 G > A (p.R2937Q) 3235 20.1 4 94 94.03 1.08 4.33 0.56 0 0
GAA NM_000152.3 c.324 T > C (p.C108) 7078 24.7 5 87 4.46 86.61 3.45 5.47 0.00 0.01
c.547-4C > G 15200 13.2 5 84 2.89 4.70 84.39 7.99 0.00 0.02
c.596A > G (p.H199R) 11616 29.2 9 86 9.13 2.95 85.73 2.18 0.00 0.02
c.668 G > A (p.R223H) 10344 31.4 5 93 92.62 1.14 4.89 1.31 0.00 0.04
c.858 + 7_858 + 8insAGCGGGC 6175 NA 3 3
c.858 + 30 T > C 3431 24.8 5 90 1.40 90.38 2.97 5.25 0.00 0.00
c.859-48 T > C
c.955 + 12 G > A 11315 23.4 4 90 89.60 3.64 3.84 2.90 0.00 0.02
c.1203 G > A (p.Q401) 8487 26.1 8 79 79.42 5.35 8.27 6.96 0.00 0.00
c.1327-18A > G 7377 26.7 9 82 8.70 5.29 81.81 4.19 0.00 0.01
c.1438-19 G > C 2511 16.9 12 75 6.49 75.07 11.59 6.85 0.00 0.00



















Table 1 Validation sample changes (Continued)
c.1581 G > A (p.R527) 8283 26.9 70 28 28.05 1.05 70.14 0.76 0.01 0.00
c.1802C > T (p.S601L) 6027 21.4 59 34 2.17 59.25 4.35 34.23 0.00 0.00
c.1888 + 21 G > A 7667 30.3 56 42 41.99 0.93 56.15 0.94 0.00 0.00
c.2040 + 20A > G 5633 27.8 7 91 6.57 1.67 90.96 0.80 0.00 0.00
c.2133A > G (p.T711) 8402 29.4 60 39 60.05 0.39 39.20 0.35 0.00 0.01
c.2331 + 20 G > A 11993 23 4 92 91.80 2.13 3.91 2.13 0.00 0.03
c.2338 G > A (p.V780I) 8957 10.2 11 83 82.93 3.74 10.73 2.57 0.00 0.03
c.2553 G > A (p.G851) 11663 21.7 5 94 93.78 0.90 4.54 0.77 0.00 0.00
GALC_1 NM_000153.2 c.328 + 19 T > A 107 0 66 34 33.64 0.00 0.00 66.36 0.00 0.00
c.329-35 G > A
c.550C > T (p.R184C) 9215 19.6 39 54 2.59 38.77 4.75 53.88 0 0
c.621 + 24 T > C 1178 17.1 82 16 1.61 15.87 0.34 82.17 0 0
c.742 G > A (p.D248N) 15664 32.8 62 35 35.28 0.5 61.78 2.43 0 0.01
c.1161 + 38 T > C 5842 29.6 56 42 0.77 42.23 0.74 56.23 0 0.03
c.1586C > T (p.T529M) 15938 25.7 16 78 2.41 16.18 3.38 78.02 0 0.01
c.1620A > G (p.T540) 25811 31.3 3 95 3.42 1.12 94.6 0.85 0 0.02
c.1671-15C > T 17257 21.1 5 93 1.17 4.9 1.05 92.86 0 0.01
c.1698A > T (p.V566) 41239 26.7 2 96 2.16 1.04 0.65 96.13 0 0.03
c.1834 + 5C > G 10158 18.2 84 15 0.21 84.13 15.16 0.41 0.01 0.09
c.1921A > G (p.T641A) 20556 23.6 2 97 2.13 0.88 96.5 0.49 0 0.01
GALC_2 NM_000153.2 c.328 + 19 T > A 193 0 85 15 15.03 0.00 0.00 84.97 0.00 0.00
c.984 G > A (p.Q328) 17041 27.1 61 37 37 1.38 60.55 1.06 0 0
c.1350C > T (p.S450) 17776 32.2 58 40 1.04 57.78 1.6 39.58 0 0.01
c.1620A > G (p.T540) 25799 31.6 3 95 3.21 1.05 94.97 0.76 0 0.01
c.1671-15C > T 22892 32.8 64 34 0.87 63.97 0.7 34.45 0 0.02
c.1685 T > C (p.I562T) 30664 31.2 58 39 1.99 38.95 1.47 57.58 0 0.01
c.1698A > T (p.V566) 42340 29.3 2 96 1.97 1.11 0.63 96.24 0 0.05
c.1834 + 5C > G 10344 13.1 73 26 0.26 73.18 25.98 0.55 0 0.03
c.1921A > G (p.T641A) 15648 23 2 96 2.19 1.04 96.42 0.35 0 0.01
GALT NM_000155.2 c.776 G > A (p.R259Q) 27403 31.3 62 32 31.51 2.92 62.00 3.55 0.05 0.02
c.817 G > C (p.D273H) 27824 32.3 61 38 0.68 37.71 60.85 0.73 0.00 0.03
GBA_1 NM_001005741.2 c.1225-34C > A 2621 22.8 2 96 96.26 2.21 1.14 0.38 0 0



















Table 1 Validation sample changes (Continued)
c.1448 T > C (p.L483P) 3331 26.4 60 38 0.99 38.04 0.9 60.07 0 0
c.1483 G > C (p.A495P) 2569 16.3 53 44 1.01 44.45 53.41 1.05 0 0.08
c.1497 G > C (p.V499) 2750 22.2 60 37 1.16 36.69 59.71 2.44 0 0
GBA_2 NM_001005741.2 IVS8-34C > A 2827 22 3 96 96.11 2.51 1.13 0.25 0 0
c.1226 A > G (p.N409S) 3813 22.9 71 23 70.52 1.1 26.86 1.52 0 0
c.1265-1317 del55 20 26.9 NA 25 25
GJB2 NM_004004.5 c.35dupG 33377 20.8 NA 18 0.74 0.33 1.28 96.64 17.63 1.01
c.35delG 34879 29.7 NA 30 29.71
HEXB NM_000521.3 c.185 T > C (p.L62S) 21320 33.2 8 86 3.63 86.44 2.33 7.59 0.00 0.02
c.362A > G (p.K121R) 14201 27.9 66 32 65.63 1.11 31.86 1.39 0.00 0.00
c.300-32C > T 792 20.5 80 17 1.77 80.05 1.26 16.92 0.00 0.00
c.558 + 45 G > A 434 18.8 81 17 17.05 1.15 80.65 1.15 0.00 0.00
c.1513C > T (p.R505W) 8306 30.9 62 37 0.52 61.77 0.92 36.78 0.00 0.01
c.1619_1620ins22 27194 NA 67
c.1645 G > A (p.G549R) 33259 34.6 84 15 15.46 0.47 83.69 0.36 0.00 0.02
IDUA NM_000203.3 c.99 T > G / p.H33Q 34 10.2 6 91 2.94 0.00 91.18 5.88 0.00 0.00
c.208C > T (p.Q70X) 4106 9.4 49 46 2.65 49.05 1.90 46.40 0.00 0.00
c.300-44C > T 10156 26.2 59 40 0.74 58.71 0.96 39.55 0.00 0.03
c.314 G > A (p.R105Q) 10809 28.7 62 34 33.71 1.86 62.39 2.01 0.00 0.03
c.543 T > C (p.N181) 12274 31.7 59 39 1.52 38.63 0.91 58.91 0.00 0.02
c.590-45 G > C 11498 28.5 63 35 1.10 35.31 62.92 0.67 0.00 0.01
c.590-8C > T 9516 30.8 63 34 1.46 63.36 1.04 34.03 0.00 0.12
c.942 G > C (p.A314) 6026 20.9 63 34 2.09 29.67 66.69 1.51 0.00 0.03
c.972 + 48A > G 1954 25.2 67 30 82.96 0.82 15.81 0.36 0.00 0.05
c.973-45 G > C
c.1081 G > A (p.A361T) 9486 26.7 60 38 37.50 1.18 59.99 1.33 0.00 0.00
c.1164 G > C (p.T388T) 3080 23.1 65 31 2.05 31.30 65.16 1.49 0.00 0.00
c.1205 G > A (p.W402X) 2679 23.2 62 32 31.88 5.30 61.55 1.27 0.00 0.00
OPA1 NM_015560.2 c.93_96dupAAAA 179 0 NA 69 69.27
c.870 + 4 T > C 8330 28.8 3 97 2.23 89.09 1.81 6.87 0.00 0.00
c.2808 G > A (p.A936) 8879 23 66 28 27.91 2.87 65.95 3.23 0.00 0.03
RECQL4 NM_004260.2 c.132A > G (p.E44) 5504 28.7 61 37 60.74 1.58 37.08 0.58 0 0.02



















Table 1 Validation sample changes (Continued)
c.738C > T (p.S246S) 10356 27.9 76 24 0.3 75.69 0.32 23.68 0 0.02
c.801 G > C (p.E267D) 5788 28.6 64 34 0.57 34.45 63.99 0.93 0 0.05
c.1258 + 18 G > A 11609 27 65 31 30.65 2.64 64.82 1.86 0 0.03
c.1621-15C > T 2331 26.6 63 34 1.12 63.32 1.54 34.02 0 0
c.2297delC 8864 25 NA 94 0.37 3.77 1.55 0.17 0.01 94.14
c.3014 G > A (p.R1005Q) 3027 27 50 48 47.9 1.06 50.21 0.83 0 0
c.3127 T > C (p.L1043L) 13424 30.6 5 94 0.77 93.66 0.99 4.53 0 0.04
c.3236 + 13C > T 1938 12 66 30 2.06 66.25 1.65 30.03 0 0
c.3393 + 8C > T 2898 24.4 61 36 1.69 61.15 1.38 35.78 0 0
c.3502 + 24 G > A 1106 20.2 64 30 29.57 2.35 64.2 3.8 0 0.09
SGSH NM_000199.3 c.337_345delins11 7735 27.4 NA 23 22.82
c.663 + 17 T > C 11973 29.6 59 39 0.93 38.84 1.24 58.96 0 0.04
c.664-39_664-38delCT 153 30.6 NA 18 0 0 0 82.35 0 17.65
c.664-36 T > C 149 30.5 82 18 0.00 18.12 0.00 81.88 0.00 0.00
c.892 T > C (p.S298P) 12564 31.7 60 38 0.93 37.61 1.13 60.31 0 0.02
c.1367 G > A (p.R456H) 8525 29.5 61 36 36.29 1.69 60.75 1.23 0 0.04
SMPD1 NM_000543.4 c.103CTGGCG[7] 5073 22.2 NA 88 88.07
c.107 T > C (p.V36A)
c.785_807del23 10467 22.1 NA 20 0.06 0.16 0.01 79.68 0.01 20.09
ZEB2 NM_014795.3 c.2083C > T (p.R695X) 20800 24.9 75 24 0.51 75.22 0.4 23.88 0 0
c.3067 + 6A > T 2632 24.3 60 39 59.95 0.68 0.53 38.79 0 0.04



















Table 2 GC content for first coding and (*) low-coverage
exons (>20X coverage)
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http://www.biomedcentral.com/1471-2156/14/6condensation algorithm, which enabled good-quality
50-bp fragment data to be lengthened and enabled
the detection of larger size deletions and duplication
events (Figure 1). This ability to detect the entire
spectrum of mutations from single nucleotide changes
to large deletions and duplications using the
NextGENe™ software represents an important
capability that a clinical laboratory has to have if they
are to be able to offer clinical sequencing tests using
next-generation sequencing data. This single run
demonstrates that NGS software like NextGENe™ has
matured sufficiently for use in a clinical environment
and that next-generation sequencers, such as the ABI
SOLiD, are ready to be deployed in clinical laborator-
ies. While our data analysis pipeline was able to de-
tect all 119 known changes, nine additional changes
(six single nucleotide changes and three deletions)
were also picked up. The laboratory was 100% con-
cordant with the NGS data identifying all 119 known
changes in the 20 samples. There were nine changes that
were identified in the NGS data that were not identified in
the Sanger sequencing data and that provided us with a
7.56% false-positive rate (Table 5).Coverage
The coverage of each coding region ranged from 643,999
reads per exon for a small gene like GJB2, to the largest
gene, which had an average of over 8,000 reads for the 79
coding regions in the DMD gene. For substitution changes,
coverage ranged from 34 to 42340 reads. For deletions, the
coverage ranged from 20 to 34879 reads. For duplications
or insertions, the coverage ranged from 179 to 33377
reads. For the single indel mutation, coverage was 7735
reads (Table 1).
Discussion
It is critical to ensure that samples selected for use in
validation of NGS carried representative changes and
mutations that a clinical laboratory expects to detect in
real-world samples.
NGS is able to detect complex mutations using targeted
amplification
Genes selected included the ACADVL, BCKDHA, CBS,
CFTR, DMD, GAA, GALC, GALT, GBA, GJB2, HEXB,
IDUA, OPA1, REQL4, SGSH, SMPD1 and ZEB2 genes.
Duchenne muscular dystrophy (DMD) is caused by
mutations in the DMD gene, the largest human gene,
spanning 2.2 Mb on the X chromosome [13,14].
Gaucher disease is an autosomal recessive disorder
where mutations in the GBA gene result in a decrease in
the activity of acid β-glucosidase. The GBA gene is an
extremely difficult gene to perform diagnostic testing on,
due to the presence of a pseudogene that is >98% identi-
cal to the active gene [15,16]. The REQL4 gene has an
atypical structure; it is a very compact gene of ~6.5 kb,
where most of the introns are less than 100 bp in length.
It is also highly repetitive and GC rich, making it diffi-
cult to amplify and sequence cleanly [17,18]. Other
genes selected for inclusion in the validation run were
mainly based on the changes they carry. One such
example is a sample with two mutations in the GJB2
gene. This sample carries a c.35delG on one allele and a
c.35dupG on the second allele (Table 1). In conventional
Sanger sequencing analysis, it is very difficult to inter-
pret the data when there are two deletions at the same
nucleotide position [19]. Both mutations in the GJB2
gene were identified on the NGS run. NGS is able to
sequence both strands independently, providing our
laboratory with not only the genotype but also the data to
determine which change is on which strand of the DNA.
Target amplification method needs to be chosen carefully
for NGS
In this study, we used a standard PCR approach to test
the sensitivity and specificity of NGS. We faced many
challenges during the initial startup phase in acquiring
and deploying an NGS instrument in a clinical laboratory
Table 3 Run statistic
Gene name Total reads Mappable reads Aligned reads (%) Reads/Exon Ave. coverage/Base Exon with min coverage Min coverage
ACADVL 2,459,557 1,352,756 55 39,971 10,278 2 957
BCKDHA_1 1,605,090 742,999 46.3 51,129 10,663 1 3695
BCKDHA_2 1,781,857 963,985 54.1 60,721 12,565 1 2390
CBS 2,032,870 1,120,111 55.1 35,875 8,729 3 1181
CFTR 2,025,300 1,042,746 51.5 23,522 4,895 15 & 27 0
DMD 1,862,128 996,238 53.5 8,385 1,821 2 68
GAA 1,956,406 1,013,418 51.8 26,236 5,431 18 1071
GALC_1 3,119,076 1,618,800 51.9 49,371 11,562 1 13
GALC_2 2,790,038 1,377,442 49.4 40,593 9,476 1 1428
GALT 1,795,122 1,086,049 60.5 60,858 15,566 8 5563
GBA_1 1,938,689 1,163,213 60 35,545 7,171 10 1277
GBA_2 1,793,280 1,075,968 60 32,945 6,641 10 541
GJB2 1,501,448 875,344 58.3 643,999 42,101 2 1
HEXB 1,851,105 897,786 48.5 34,570 7,641 12 1187
IDUA 1,275,727 637,864 50 22,550 4,978 1 4
OPA1 1,933,855 964,994 49.9 19,893 5,003 17 & 23 0
RECQL4 2,053,423 903,506 44 21,494 3,935 1 139
SGSH 1,845,441 992,663 53.8 47,870 9,990 1 3847
SMPD1 1,505,628 864,230 57.4 94,517 10,552 2 1986
ZEB2 1,653,612 1,036,815 62.7 82,365 8,394 8 1921
Average 1,938,983 1,036,346 53 71,620 9,870
Run statistic from a single SOLiD v3 quad for all 20 barcoded samples.
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hundreds if not thousands of PCR reactions a day for use
in Sanger sequencing, but this enrichment strategy would
not work for NGS; it involves too many labor-intensive
steps to accurately quantitate individual PCR amplicons
before it can be pooled for use in the NGS chemistry pipe-
line. This labor-intensive manual process will raise costs
and lengthen the time of the entire process. Laboratories
will find it hard to continue to use standard Sanger
sequencing enrichment techniques on a routine basis,
because of the need to exploit the full capacity of the NGS
instrument to minimize costs. On the SOLiD v3 instru-
ment, we are able to interrogate up to 2.4 Mbp of a region
of interest in a single quad. The cost in time and effort to
generate individual PCR amplicons for an entire 2.4-Mbp
region of interest is prohibitive and raises the chances that
a mistake will occur. Even if long PCR techniques
could be employed as the enrichment technique, it
would require 240, 10-kb individual reactions to
enrich for a 2.4-Mbp region.
It is clear that, to manage the workflow of a larger num-
ber of amplicons for gene panels, clinical laboratories will
need to consider target enrichment methods, such as
multiplex PCR (Fluidigm™), microdroplet-based PCR
(RainDance™), or in solution-based PCR (AgilentSureSelect™). Jones et. al [20]. have recently demonstrated
the use of microdroplet-based PCR for the testing of 25
genes for congenital disorders of glycosylation (CDG) in a
clinical laboratory. In the work performed by Jones et. al.,
it was shown that even after using target enrichment
methods, some exons fail to give adequate coverage and
still need Sanger sequencing to complete the clinical test.
Sanger sequencing will continue to play an important role
in the clinical laboratory for assay completeness, both for
sequencing low-coverage and difficult regions in a gene
and for confirmatory studies once a mutation is identified
in a proband and additional family members need to be
tested. Given our initial approach of adapting the enrich-
ment method used for standard Sanger sequencing, we
have demonstrated any change within the boundaries of
custom-designed primers flanking the region of interest
(eg, exons) can be detected successfully.
Coverage
Using coverage data as the sole indicator of whether a
change was real is difficult. The nine false-positive
changes that were picked up had a median coverage of
approximately 400 reads and a mean of approximately
3,600 reads. As a contrast, confirmed changes had
approximate median coverage of 5,300 reads and an
Table 4 Number of changes
Gene name Sanger NextGENe % called
BCKDHA_1 2 2 100%
BCKDHA_2 4 4 100%
CBS 2 2 100%
CFTR 3 3 100%
DMD 6 6 100%
GAA 20 20 100%
GALC_1 12 12 100%
GALC_2 9 9 100%
GALT 2 2 100%
GBA_1 5 5 100%
GBA_2 3 3 100%
GJB2 2 2 100%
HEXB 7 7 100%
IDUA 13 13 100%
OPA1 3 3 100%
RECQL4 11 11 100%
SGSH 6 6 100%
SMPD1 3 3 100%
ZEB2 2 2 100%
Total changes 119 119 100%
Summary of the number of changes picked up on the validation run.
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of reads for actual confirmed changes are approximately
15-fold higher compared to false-positive changes. As the
number of reads for both confirmed and false-positive
changes overlaps significantly, we are unable to use just
the number of reads as the sole indicator. In this study, we
see a great overlap in coverage between the number of
reads for substitution mutations and with smaller
insertion/deletion mutations. To detect larger deletions/
duplications using NextGENe’s™ condensation function,
the number of reads was effectively reduced. The GBA_2
sample, c.1265_1319del55 mutation had only 20 reads,
compared to the GJB2 sample, which has a single base
deletion, c.35delG mutation that had 34,879 reads. Simi-
larly, the OPA1 sample, c.93_96dupAAAA mutation has
only 179 reads compared to the GJB2 sample, c.35dupG
mutation, which had 33,377 reads. In an effort to try to
determine an appropriate coverage threshold, simulation
experiments were run for mutation c.2052_2053insA in
the CFTR gene. A varying number of reads that align to
the region were randomly selected and used for analysis.
We performed 80 simulations with the number of reads
selected varying from 15 to 50 reads for every 10,000
reads. Coverage for the insertion varied from 8 to 43. For
some of the simulations, NextGENe was able to detect the
insertion with coverage as low as 8 reads. We chose 20reads as the average threshold. Other groups have also
expressed a similar viewpoint [21-25]. In work performed
by De Leeneer K. et. al., the authors have performed a
detailed analysis to determine the coverage needed during
a NGS sequencing run given two variables (quality score
of data and sequencing errors) to detect heterozygous
changes. In their paper, they have determined that data
with a quality score of 30 will require a minimum 18X
coverage if sequencing error is at 15% [24]. Dohm J et. al.
in their study found bona fide SNPs by applying high
coverage of >20X [24].
Confidence score
Software has a Phred-like confidence score calculated with
a novel SoftGenetics algorithm. The software algorithm
takes into account multiple variables to calculate a final
probability that any one change is a true. A phred score of
10 means there is approximately a 1 in 10 chance that the
change is the result of an error, while a phred score of 30
represents a 1 in 1000 chance that the change is an error.
This Phred-like score gives us greater confidence in deter-
mining true and false-positive changes. In our study, we
have seen real changes with Phred-like confidence scores
averaging a score of 24 with a minimum score of 9.4 and a
maximum score of 34.6 (Table 1). Some changes detected
using the condensation algorithm does not have a Phred-
like confidence score. Confidence score of nine and above
along with coverage above 20X makes it more likely that a
change is real.
Proportion of bases
Another indicator is the relative proportion of mutant
compared to the wild-type base. In one of the samples
we ran, there is a heterozygous c.1504 C > G (p.L502V)
missense mutation in the ACADVL gene. This mutation
had 5869 reads showing an approximately equal propor-
tion of the wild-type C allele (60%) compared to the mu-
tation G allele (40%). Our validation data set suggests
that real heterozygous calls should be present in the data
in approximately equal proportion and can range as to
as much as 70% wild-type to 30% mutant, whereas
homozygous/hemizygous calls should consist almost
exclusively of the mutant allele but can range as much
as 20% wild-type to 80% mutant. The proportion of
bases called will never be exact, due to the presence of
nonspecific amplification that was sequenced and
aligned back to the regions of interest. This is
compounded by errors generated during next generation
sequencing wet bench process and errors generated by
the Solid instrument during sequencing.
NGS pipeline in a clinical laboratory
Most clinical laboratories are very well equipped and






Figure 1 Representative mutation as detected on Sanger and SOLiD platforms. Panes 1A & 2A represent the SOLiD and Sanger data for
ACADVL c.1504C > G (p.L502V) mutation. Panes 1B & 2B represent SOLiD and Sanger data for CFTR c.1521_1523delCTT mutation. Panes 1C & 2C
represent SOLiD and Sanger data for CFTR c.2052_2053insA mutation. Panes 3 and 4 represent SOLiD and Sanger data for the GBA
c.1265_1319del55 mutation.
Chin et al. BMC Genetics 2013, 14:6 Page 11 of 13
http://www.biomedcentral.com/1471-2156/14/6requires multiple steps. While most clinical laboratories
will not find it difficult to perform the wet bench work
required to perform a NGS run, it is a challenge to
maintain the same level of consistency as could be
achieved easily with a Sanger sequencing pipeline.
The current NGS pipelines involve many interdependent
steps, and a major challenge faced by our laboratory was
how to accurately and consistently quantitate small
amounts of the enriched library that are present in each
single step of the process. A subtle change in quantitycould result in a bad library preparation and lead to a less
than ideal data set, especially if loading the quad to its
maximum capacity. Equal deep coverage of at least 20
reads per base across every region of interest is needed to
ensure that all changes are picked up accurately by
the laboratory.
Changes in laboratory structure
Clinical laboratories often lack experienced bioinformatics
staff and the necessary computing infrastructure within a











SNP 102 108 6 5.88%
Duplication /
Insertion 9 9 0 0.00%
Deletion 7 10 3 42.86%
Indel 1 1 0 0.00%
Total (Overall) 119 128 9 7.56%
Summary of false-positive rates per change category.
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analysis programs available on the market. The few that
exist were developed for use by programmers and
bioinformatics specialists. This dearth of software
packages, which are both 'laboratorian' friendly and
powerful enough to perform de novo detection of the
entire mutation spectrum, hinders developments that
would enable to use of NGS fragment capabilities to
perform targeted resequencing projects. We selected
SoftGenetics NextGENe™ software package as it is
designed to detect the entire mutation spectrum, including
small and large indels using data generated from a 50-bp
fragment run. Our laboratory has demonstrated that we are
able to leverage the power of SOLiD’s 50-bp fragment run
to detect not only single nucleotide changes, but also small
and large indels. This is possible due to a proprietary indel
detection process called condensation, developed by
SoftGenetics [26]. The condensation tool is used to polish
and lengthen short sequence reads into fragments that are
longer and more accurate. The short reads from the SOLiD
System are often not unique within the genome being
analyzed. By clustering similar reads containing a unique
anchor sequence, data of adequate coverage are condensed;
short reads are lengthened and instrument errors are
filtered from the analysis. This stage helps to prepare data
for analysis in applications such as SNP/Indel detection by
statistically removing many of the errors, while maintaining
true variations. The reads used for each condensed read are
recorded to maintain allele frequency information. In
addition, the condensation tool can be set to automatically
run multiple cycles, further increasing the read lengths.
Condensation operates without referring to a reference
sequence. Reads are clustered using 12-bp anchor
sequences within the reads. Each possible 12-bp sequence
within the reads is considered for indexing. All reads
containing this exact sequence are clustered together to
form a group. The group of reads is further sorted by the
flanking shoulder sequences, immediately upstream and
downstream from the anchor sequence, into subgroups. A
consensus read, generally 1.6 times the original read length,
is created for each subgroup. By removing many low-
frequency, biased calls and improving alignment accuracyby lengthening reads, the condensation tool is useful for
preparing data prior to indel detection. NextGENe™ then
aligns the consensus reads to the reference sequence.
NextGENe™ can be run by a laboratory technician, which
is an important consideration for a clinical laboratory. A
laboratory technician who has been trained to analyze
Sanger sequencing data does not necessarily have the
programming skills to perform NGS analysis. Skilled
professional programmers or bioinformatics specialists are
needed to work in partnership with laboratory directors,
genetics counselors, and clinicians to interpret the massive
amount of data generated in a single NGS run.
Due to the immense capacity to generate data from a
NGS platform, clinical laboratories will not perform single-
gene analysis on the NGS platform. We are able to use the
increased capabilities of the NGS platform by raising the
number of genes being analyzed at a time. As the number
of genes in a gene panel increases, the potential number of
false positives identified will correspondingly go up. Clinical
laboratories will deal with a larger number of false-positive
changes in order to avoid missing any real disease-causing
mutations. As with any clinical test, changes identified from
a NGS platform will need to be confirmed using an alterna-
tive technology, such as Sanger sequencing. It is important
that clinical laboratories perform such confirmation to
determine the validity of calls generated by the NGS data.
We have been able to identify three indicators (coverage of
above 20 reads, confidence score of 30 and above and pro-
portion of bases for heterozygotes that can range as skewed
as 70% wild-type to 30% mutant and for homozygous as
much as 20% wild-type to 80% mutant) to help to
determine whether a change that is detected is real.
Cost considerations when implementing NGS in a clinical
laboratory
The cost of implementing a NGS system in a laboratory is
not confined to the cost of the instrument package as
provided by the manufacturer. There are many pieces of
ancillary equipment required, and their availability will be
critical to the success of the NGS setup in the laboratory.
Equipment such as a powerful computer and secure data
storage are required in the laboratory to handle the massive
amounts of data. Cloud computing is an option that has
emerged as NGS was developed over the last few years.
While this is an alternative, the clinical laboratory will need
to identify a secure HIPAA-compliant cloud provider that
will be able to support clinical needs. While the cost
of such a computer and storage cluster is reasonable,
laboratories will need to budget additional funds to cover
the purchase of such ancillary equipment.
Conclusions
In conclusion, we have demonstrated that NGS technology
is ready to be deployed in clinical laboratories. The
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was able to detect all 119 changes which were identified
previously using Sanger sequencing. However, NGS and
associated technologies are still in their infancy, and
clinical laboratories will need to invest significantly in staff
and infrastructure to build the necessary foundation for
success. It has been suggested by many parties that the
importance of targeted gene sequencing panels will
decrease as the cost of NGS decreases. There is no need to
just perform a targeted sequencing run when the same
information can be extracted from a whole-exome or
-genome analysis dataset. A recent study by Snyder
et al. [27] suggests that, due to the size of the target
that is being interrogated (exomes/genomes versus 2.4
Mbp), the lower depth of coverage reduces the sensi-
tivity of variant detection. This affects the confidence
of a clinical laboratory to detect all pertinent variants
in our target genes. As such, targeted gene sequen-
cing panels will continue to play an important role in
clinical sequencing, until such time that whole
exomes and genomes are able to reach the same level
of high, even coverage as a targeted sequencing panel.
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